Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID-ELAPSE: bupropion for fatigue in post-COVID syndrome
2025-524443-12-00Phase 2Authorised
- Sponsor
- Goethe University Frankfurt
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID syndrome comparing Bupropion with Placebo (2 arms). Primary endpoints: Change in fatigue severity and Change in physical function. Planned start Apr 2026; status: authorised.
02
Drugs
bupropion
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2025-524443-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524443-12-00.